Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.

Autor: Eleutherakis Papaiakovou, Evangelos, Terpos, Evangelos, Kanellias, Nikolaos, Migkou, Magdalini, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Fotiou, Despoina, Malandrakis, Panagiotis, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Kostopoulos, Ioannis V., Tsitsiloni, Ourania, Tsirigotis, Panagiotis, Dimopoulos, Meletios-Athanasios, Kastritis, Efstathios
Předmět:
Zdroj: Leukemia & Lymphoma; Dec2023, Vol. 64 Issue 13, p2140-2147, 8p
Abstrakt: Autologous stem cell transplantation (ASCT) remains a standard therapy for multiple myeloma (MM) patients. Our study aimed to assess the impact of daratumumab-containing induction on stem cell (SC) mobilization, apheresis and hospitalization. We evaluated 200 newly diagnosed MM patients that were mobilized for SC collection and which received induction with (N = 40) or without daratumumab (N = 160). Dara group patients required more frequent use of plerixafor, larger collection volumes, and had lower SC yield. 87.5% (35/40) of dara group patients achieved the planned yield of ≥ 5 × 10^6 CD34+/kg for at least one transplant compared to 96.2% (154/160) of patients in the non-dara group. Dara group patients had delayed hematopoietic recovery (11 vs 10 days for PMN > 0.5 × 10E9/l), required more transfusions (4 vs 2 plts), prolonged hospitalization (20 vs 18 days), more febrile episodes and prolonged antibiotic administration. Despite daratumumab effect patients finally achieved a successful stem cell collection and proceeded to transplant. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje